Table 12.6a

Immunosuppression Use for Induction, 1996 to 2005

Recipients with Lung Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 836 948 893 922 977 1,083 1,054 1,099 1,185 1,409
With Immunosuppression Info 764 931 885 895 950 1,065 1,030 1,088 1,163 1,360
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 22.6% 19.5% 13.9% 12.6% 11.9% 8.8% 6.4% 4.9% 5.4% 3.8%
OKT3 3.7% 2.5% 3.5% 3.4% 2.6% 1.0% 0.6% 1.1% 0.5% 0.9%
Thymoglobulin 0.0% 0.0% 0.0% 1.9% 6.0% 5.4% 8.3% 3.0% 3.7% 3.0%
Zenapax 0.0% 0.0% 4.9% 9.6% 14.6% 11.3% 13.7% 15.6% 14.7% 12.1%
Simulect 0.0% 0.0% 0.3% 3.2% 8.3% 12.8% 15.0% 19.6% 23.0% 18.3%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.9% 3.6% 5.2%
No Induction Drugs Recorded 73.8% 78.2% 77.5% 69.5% 56.9% 61.1% 56.3% 55.9% 50.0% 57.4%


Source: OPTN/SRTR Data as of May 1, 2006.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.